lutetium-177: psma guided treatment | #prostatecancer | #markscholzmd | #pcri
Published 1 year ago • 16K plays • Length 11:01Download video MP4
Download video MP3
Similar videos
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
3:17
safety and efficacy of 177lu-psma-617
-
2:24
eclipse - a randomized phase 3 trial for 177-lu-psma-i&t in patients with mcrpc
-
1:02
dr. gafita on prognostic models for treatment with 177lu-psma-617 in mcrpc
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
7:14
vision study
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
5:06
psmaddition: 177lu-psma-617 plus soc vs. soc alone in metastatic hormone-sensitive prostate cancer
-
10:28
anzup therap study (lu-177 psma-617 vs. cabazitaxel): overall survival after 3 years follow-up
-
4:48
vision: lu-177-psma-617 in mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
1:24
luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer
-
11:23
therap study: lu-psma vs. cabazitaxel #asco20 #anzup
-
4:00
therap trial and effectiveness of lu-psma-617
-
0:16
lutetium-177 psma therapy
-
0:28
177lu-psma-617 for metastatic castration-resistant prostate cancer
-
15:35
lu-psma radioligand therapy
-
4:46
lutetium-177–psma-617: appropriate and potential off-label utility
-
1:10:05
psma scans & pluvicto (lutetium-177) in 2022 | geoffrey johnson, md, phd | pcri conference 2022